INTRODUCTION

Incidence of human immunodeficiency virus-infection
The United Nations reported that at the end of 2017, worldwide about 36.9 million people are living with human immunodeficiency virus (HIV) infections, which include 1.8 million children [1] . Annual number of HIV infections in the United States peaked in the mid-1980s, then decreased through the early 1990s, and remained relatively stable through 2010 [2, 3] . The Centers for Disease Control and Prevention estimated that at the end of 2015, 1.1 million persons aged 13 and older were living with HIV infection in the United States, including 162500 (15%) persons whose infection had never been diagnosed. From 1987 to 2015, about 507351 people died from HIV disease [4] . The highest incidence of HIV in United States is in southern states, which are home to around 45% of all people living with HIV. This accounts for about 50% of the new diagnoses every year in the United States [5] . Around 70% of annual new HIV infections occur among gay and other men who have sex with men, among whom African American men are most affected, followed by Latino/Hispanic men. Heterosexual African American women and transgender women of all ethnicities are also disproportionately afflicted [4] .
Clinical evidence of HIV-related liver damage
Liver disease is now recognized as the most common non-acquired immune deficiency syndrome (AIDS) related cause of death among HIV-infected patients and accounts for 14%-18% of all deaths in this group [6] [7] [8] . Approximately 50% of deaths among hospitalized HIVinfected patients in the antiretroviral therapy (ART)-era have been attributed to liver problems [9, 10] . While HIV mono-infection elevates liver transaminase levels, the exacerbation of liver injury is even more prominent when HIV patients are co-infected with hepatotropic viruses [hepatitis C virus (HCV) and hepatitis B virus (HBV)] or are exposed to liver-damaging substances, such as alcohol [11] . Thus, managing the liver complications is very important during the care of HIV-infected individuals [12] . After 30 years of HIV pandemic, with the wide use of effective ART that increased HIV-infected patient survival, liver injury became recognized as an important clinical manifestation of HIV-infection affecting its outcomes [13] . It has been shown that the liver plays a key role in the clearance of circulating viral particles in the blood as supported by data obtained in simian immunodeficiency virus (SIV)-infected monkeys [14] [15] [16] [17] . Liver transaminases are frequently elevated in the sera of HIV-infected patients even in the absence of accompanying viral hepatitis [18] . In addition, there is an association between HIV RNA content and liver fibrosis [19] . Liver manifestations accompanying HIV-infection may exist with no relationship to ART treatment outcomes and thus, whether HIV infection itself, immunodeficiency, and long-term ART are associated with the development of chronic liver injury is still a matter of debate. Previously, HIV-related liver injury was interpreted as a consequence of opportunistic infections or AIDS-induced malignancies, but recent data indicate that HIV itself may affect the liver. In HIV-monoinfected patients, high HIV-1 load was shown to be an independent risk factor for the development of chronic elevated alanine aminotransferase (ALT) [20, 21] and steatosis [22] . Furthermore, a detectable HIV load combined with an aspartate aminotransferase (AST)-to-platelet ratio index (APRI) greater than 1.5 is the risk factor of liver disease development and is surrogative for significant fibrosis [23] . The impact of HIV viremia on liver fibrosis has been also described in HIV/HCV-coinfected patients [24] . Nevertheless, many clinical and epidemiological studies reported that HIV directly induces liver fibrinogenesis [25, 26] in patients without viral hepatitis co-infection. A large North American clinical investigation demonstrated that HIV RNA plasma levels were associated with increased Fibrosis-4 (FIB-4) score in the absence of HBV, HCV, ART or alcohol use [27] . Studies from three groups using transient liver elastography detected liver injury in HIVmonoinfected patients [28] [29] [30] [31] [32] , which correlates with high plasma HIV RNA levels [20] . Immunodeficiency-associated liver injury was also reported in a retrospective analysis of HIV-monoinfected patients with increased ALT values and a CD4 + cell count less than 200 cells/mL [21] . In a crosssectional study, CD4 + cells level less than 200 /mL was considered as a predictor for abnormal liver stiffness [30] . In addition to HIV-induced hepatotoxicity in ART nonexposed individuals, long-term treatment of HIV-patients with ART might be hepatotoxic, and especially this is a case for the old drugs, like azidothymidine, nevirapine and nucleoside analogs [33] [34] [35] . Previous observational data investigating risks for death suggested possible chronic ART-related hepatotoxicity [36, 37] . Importantly, recent Spanish cross-sectional study found that prolonged ART exposure caused advanced liver fibrosis in HIVmonoinfected patients, but conversely, was protective for advanced fibrosis in HCV-coinfected patients. Didanosine and stavudine were identified as being of particular risk for fibrosis in both HIV-monoinfected and HCVcoinfected persons [38] . This observation was confirmed by several cross-sectional studies [20, 30, 39, 40] . With further development of anti-HIV drugs, modern ART became less hepatotoxic. However, there are still reports on ARTassociated hepatic syndromes, such as nonalcoholic fatty liver disease and non-cirrhotic portal hypertension in HIV-positive individuals [41] . Hepatotoxic effects of ART are developed via multiple mechanisms, including mitochondrial damage, generation of liver-toxic products by drug metabolism, drug-induced hypersensitivity reactions and immunosuppression [42, 43] . Viral load is essential to trigger liver damage. In fact, close association between AST levels and HIV viral load has been shown in HIV-infected patients [18] . In addition, mathematical modeling of liver enzyme elevation in HIVmono-infection also revealed that significant elevation of alanine aminotransferase coincides with increased HIVload [44] . These data were confirmed by experimental studies on HIV-infected humanized mice demonstrating that the decrease in human albumin levels correlated with a decline in CD4 + cells in the liver and with an increase of HIV-1 viral load [45] .
HIV AND LIVER CELLS
The liver contains parenchymal cells (hepatocytes) and various non-parenchymal cells. Hepatocytes can produce a characteristic protein response to noxious stimuli, termed the acute-phase response, which in turn, regulates immune cell responses. Non-parenchymal cells, such as Kupffer cells, sinusoidal endothelial cells, hepatic stellate cells (HSC), dendritic cells, and liverassociated lymphocytes play a role in immunologic surveillance within the hepatic sinusoids. Kupffer cells are located mainly in the periportal area, which allows them to phagocytose and eliminate pathogens entering the liver via the portal blood flow [46] . There is growing evidence to suggest that HIV may interact with several hepatic cell types. However, detailed evaluation of HIV replication in liver tissue has not been addressed to date. To this end, several possibilities can exist. First, viral antigens per se may engage liver cell populations without the need for viral infections. Liver cells may respond to viral antigens, which are the part of infectious virions (full viral particle) or defective virions that are unable to productively infect any cell type. These viral proteins may also represent antigens that have been shed from virions and are circulating freely [47] . In the case of HIV, these soluble antigens consist largely of the envelope glycoprotein 120 (gp120) and the trans-activator protein Tat. Other HIV proteins from the lysis of HIV-infected cells may be at a low concentration since they are diluted in the systemic circulation and therefore, unlikely demonstrate any appreciable effect in vivo. In addition to interactions between viral antigens and liver cells, there is evidence to suggest that several distinct liver cell populations, including hepatocytes, hepatic stellate cells, and Kupffer cells also support productive HIV infection [47] . HIV RNA has been detected in primary human hepatocytes both ex vivo [48] [49] [50] and in vitro [51, 52] . We and others have shown that many hepatocyte cell lines are permissive to low level of HIV infection in vitro [53] [54] [55] . However, the nature of receptors for viral entry on hepatocytes are still under debate. As an option, it might be CXCR4 and CCR5 in Huh7.5 cells, which serve for HIV attachment/entering [56] . In fact, several studies confirmed that HIV-1 productive infection in primary hepatocytes and hepatoma cell lines is CD4-independent [55, [57] [58] [59] . Another optional entry for HIV in hepatocytes is through plasma membrane glycosphingolipids, such as Glycolipid galactosyl ceramide [60] . Usually, the level of HIVinfection in hepatocytes is low, but can be significantly potentiated by second hits like co-infection [53] or alcohol.
Our laboratory recently found increased HIV RNA levels in primary human hepatocytes and Huh7.5 cells that express CYP2E1, which becomes very visible upon exposure of infected cells to ethanol. In these cells, ethanol metabolism and specifically, ethanol metabolite acetaldehyde increased HIV RNA levels [53] . Resident liver macrophages, Kupffer cells, have higher infection levels than hepatocytes. They were shown to be infected by HIV in vivo [48] [49] [50] . In vitro studies suggested that this infection is productive [51, 52] . Thus, Jiang et al [61] detected intracellular expression of p24
antigen in Kupffer cells, endothelial cells and hepatocytes. Lang et al [62] , also demonstrated HIV infection in Kupffer cells and intrahepatic lymphocytes by immunostaining for HIV proteins.
Infection of Kupffer cells and hepatocytes with HIV was confirmed by several approaches. First, in vivo studies support the presence of HIV pro-viral DNA in liver tissue, particularly, in Kupffer cells and isolated hepatocytes [63] . Second, the presence of HIV proteins has been detected in parenchymal and non-parenchymal liver cells by immunohistochemistry [26] . The direct interactions occur between HIV and various liver cells, including hepatocytes, Kupffer cells, inflammatory mononuclear cells, and sinusoidal cells [48, 64] . In addition to hepatocytes and Kupffer cells, HIV replicates in HSC, which plays a significant role in HIVinfection pathogenesis [26, 65] . Further, it was a direct correlation between the expression of HIV in liver cells and severity of liver damage in HIV-infected patients.
Role of HIV-induced hepatocyte apoptosis in inflammation/fibrosis development
HIV induces hepatocyte cell death. It is not clear yet whether pro-apoptotic effects and release of pro-inflammatory cytokines by these cells come from intracellular HIV replication or simply from hepatocyte interactions with HIV antigens [26, 66] . However, parenchymal cell apoptosis serves as a basis for inflammation/fibrosis promotion. As known, HIV glycoproteins stimulate hepatocyte expression of the tumor necrosis factor (TNF)-related apoptosis inducing ligand, which mediates apoptosis [67] . Gp120 can also activate the hepatic expression of interleukin (IL)-8, from two different laboratories reported that like dendritic cells, HIV-infected HSCs can transfer the virus to infect the susceptible CD4 + lymphocytes [79, 80] . The association of HSCs with lymphocytes during liver inflammation, their localization below the fenestrated sinusoidal endothelium and the direct in vivo interaction with lymphocytes has been confirmed by confocal microscopy [81, 82] . Additionally, when compared to cell free virus, cell-associated HIV-1 enter CD4 + T cells, thereby causing effective infection.
Finally, HIV-infected HSCs were shown to activate the neighboring cells, such as hepatocytes by providing an important intrahepatic source of HIV proteins [56, 83] . Hepatocyte apoptosis and inflammation may also contribute to HSC activation, thereby causing liver fibrosis progression. Hepatocyte apoptosis induces pro-fibrotic activity of hepatic stellate cells in both HIV/HBV and HIV/HCV co-infections [65] . We have recently shown that apoptotic bodies from HIV/HCV pathogen-expressing hepatocytes trigger pro-fibrotic and to a lesser extent, pro-inflammatory changes in HSC, thereby promoting fibrosis development [53] . Furthermore, in HCV-HIV coinfected hepatocytes, the level of HCV RNA and HIV RNA is higher than in monoinfected hepatocytes, which becomes evident only when HCV-HIV-induced cell apoptosis is blocked by pan-caspase inhibitor. These in vitro pro-apoptotic effects of co-infection are more prominent when hepatocytes are plated on gels that mimic increased liver stiffness [53] . In this study, we have also demonstrated that increased liver stiffness potentiates apoptotic cell death in co-infected hepatocytes and thus, the progression of liver disease may be faster if HCV co-infection occurs in HIV + patients with already fibrotic liver. HIV-induced liver injury and specifically, hepatocyte apoptosis is significantly potentiated by alcohol exposure. Alcohol was shown to cause liver damage via oxidative stress accompanied by the formation/release of free reactive oxygen species that activate Kupffer cells. In addition, oxidative stress induces macromolecular damage to hepatocytes finally leading to apoptosis. In HIV-infected patients, alcohol causes increased activation of macrophages and hepatocyte apoptosis, which promote HSCs activation via nuclear factor kappa-beta (NF-kB) and activator protein 1, thereby increasing production of proinflammatory and profibrotic cytokines [53, 84] . Figure 1 , depicts the possible mechanisms of interactions between the HIV-infected liver cells.
ROLE OF MICROBIAL TRANSLOCATION AND MICROBIOTA IN HIV INDUCED LIVER DAMAGE
It became clear now that microbial translocation is an important determinant of clinical manifestations and HIV disease progression [76] . Damage to the intestinal mucosa in patients with HIV leads to disruption of the gut epithelial barrier, which facilitates leakage of luminal microbial products to translocate into the portal and systemic an important mediator of hepatic inflammation [68] . In vivo evidence of HIV-specific hepatocyte apoptosis come from the studies on humanized mice models. Thus, study from our group [45] explored the immunopathogenesis of HIV-1-induced depletion of human hepatocytes in HIV-1-infected humanized mice dually reconstituted with human hepatocytes and human immune system. This advanced mouse model recapitulates multiple components of liver damage by HIV-1-infection in humans, including:
(1) HIV-1-induced depletion in liver CD4 + cells; (2) decreased albumin levels; (3) liver immune activation; and (4) human hepatocytes death. In a different study, chronically HIV-1-infected humanized mice also showed reduction of albumin levels and restoration of liver synthetic function by ART [69] , indicating the significance of replicating virus. Collectively, these findings suggest that HIV is expressed in human hepatocytes. However, the level of HIV-infection in parenchymal cells is low when compared to HIV permissive immune cells. This indicates that hepatocytes may serve as a silent reservoir of HIVinfection. Furthermore, Fromentin et al [70] , reported that hepatocytes can bind and internalize HIV-1 particles as well as transmit cell surface-associated virus to CD4 + T cells in the liver through intercellular cell adhesion molecule-1/lymphocyte function-associated antigen-1 interactions. In addition, we observed that apoptotic bodies generated from hepatocytes with removed surface structures, can still infect HIV-permissive cells (unpublished data), indicating that HIV penetrates inside of hepatocytes and is not always only attached to cell surface. This cell-to-cell exchange of infectious cargo, in turn, might facilitate viral dissemination in the liver and throughout the whole organism. Moreover, HIV-infected hepatocytes can activate natural killer T cells as this cell population is enriched in the liver and is susceptible to productive HIV-1 infection [71] . Kupffer cells are known to play a key role in induction of hepatocyte apoptosis and to be involved in promotion of steatosis [72] . Moreover, recent studies showed that SIV and HIV-infected macrophage/monocytic cells secrete elevated levels of transforming growth factor beta, which, in turn, activate HSCs to induce fibrosis [17, 73] . Engulfment of apoptotic hepatocytes may serve as the activators for Kupffer cells [74] , thereby contributing to liver inflammation development.
Not only macrophages, but HIV-specific T cells may also promote liver fibrosis, but the evaluation of intrahepatic virus-specific T cell responses is difficult due to the low frequency of these cells in the liver and limited availability of liver biopsy material from patients [75] . A study performed in HIV/HCV co-infected patients demonstrated the presence of both HCV-specific and HIV-specific T cells in the liver [76] . As also demonstrated in this study, HIV-specific T cells were more functional than the HCV-specific T cells, and therefore, better equipped to promote HSCs activation. Once HSCs are activated, they exhibit properties of professional antigenpresenting cells and stimulate T lymphocyte proliferation by endocytosing the peripheral particles [77, 78] . Studies circulation [85] . Gut microbial translocation leads to hepatic injury primarily via increased hepatic levels of bacterial lipopolysaccharides (LPS), causing hepatic inflammation by one of three mechanisms: (1) Recruitment and activation of inflammatory cells; (2) Indirectly induced systemic immune responses and promotion of hepatocyte cell death [86, 87] ; and (3) Production of cytokines and acute phase cytokines, such as transforming growth factor beta 1, IL-6 and IL-10 [88, 89] . As our understanding of gutliver axis has improved, this pathological translocation of bacterial degradation products is recognized as a significant mechanism for triggering progressive liver damage in many disease states, including alcoholic and non-alcoholic liver diseases.
Further, HIV-infection directly targets gut lymphocyte tissue and preferentially depletes CD22 + , CD4
+ cells and TH17 cells [90] [91] [92] [93] . In addition, HIV viral proteins increase the production of inflammatory cytokines by gut epithelium, leading to enhanced apoptosis of epithelial cells and breakdown of tight junctions [94] [95] [96] . Notably, this gut barrier dysfunction appears to persist even after successful treatment with ART, since soluble CD14 (a surrogate marker for the presence of bacterial LPS) remains elevated even after systemic markers of infection (such as viral load and IL-6) have normalized [97, 98] . In both cases, this leads to increased intestinal permeability and hepatic exposure to LPS. LPS exerts its effect in the liver primarily by activating the Kupffer cells and HSCs via the Toll-Like-receptor 4 (TLR4)-mediated signaling pathway [46, 99, 100] , which further activates three major transcriptional complexes: NF-kB, activator protein 1 and interferon regulatory factors. The specific actions of these transcriptional complexes are poorly understood, but the net effect of their activation is an upregulation of the inflammatory/fibrotic HSC phenotype and potentiation/ increase in longevity of HSC cell lines [98] . In the case of Kupffer cell activation via TLR signaling, the mediators upregulated by the TLR4 pathway include TNF-α, IL-1, and IL-6, which promote liver fibrosis by directly activating HSCs or by priming and recruiting other inflammatory leukocyte populations [99, 100] .
ALCOHOL-INDUCED LIVER INJURY IN
HIV-INFECTED PATIENTS
In United States, about 50% of deaths from HIV-induced liver disease are due to alcohol-induced liver damage but the mechanisms, by which alcohol potentiates HIVinfection are not clear [12] . Chronic alcohol consumption is observed in 30% of HIV-infected patients [101, 102] and may result in alcoholic hepatitis, which leads to liver deterioration [103, 104] . Alcohol, via its metabolic effects, depletes liver-protecting factors (like major anti-oxidant glutathione), thereby enhancing the drug-related toxicity [105] [106] [107] [108] . The immunosuppressive properties of chronic alcohol consumption enhance viral replication, and the combination of alcohol and chronic infection with hepatotropic viruses has synergistic and deleterious effects [109, 110] . Both alcohol misuse and addiction significantly enhance the risk of advanced fibrosis and cirrhosis in HIV mono-infection as well as in HIV/HCV co-infection [111] . These observations were confirmed by Chaudhry et al [112] . Alcohol use was categorized according to National Institute on Alcohol Abuse and Alcoholism instructions, and APRI was used to classify the liver function: APRI greater than 1.5 is considered as a significant liver disease [112, 113] . It has been clearly demonstrated that alcohol drinking is an important, independent and variable risk factor for liver fibrosis in HIV-infected patients. In this regard, ART/alcohol associations are significant factors influencing liver function. For instance, in alcohol misusing patients with compromised liver function, proper dosing of ART becomes challenging since the liver also metabolizes these drugs. Thus, the doses should be adjusted properly, otherwise liver dysfunction could lead to harmful accumulation of some anti-HIV drugs. Even though there are only a small number of drug interaction studies assessing the outcome of alcohol misuse on ART, a few of them have indeed documented an increased risk of ART-induced hepatotoxicity in alcohol abusing patients, particularly co-infected with HCV ones [101, 114] . So far, little attention has been paid to the mechanisms underlying ART hepatotoxicity in combination with alcohol or other cofactors. Some recent studies have demonstrated that liver injury induced by alcohol and ART shares numerous potential mechanisms. It is strongly believed that both alcohol and ART can adversely affect the same cellular targets (mitochondria, cytokines, and proteasomes) [111] . Hence, there is a critical need for studies that describe mechanisms of ART-induced liver toxicity, particularly, in combination with alcohol. These studies will be helpful in evaluating potential therapeutic interventions. However, ART-induced drug toxicity is not the only mechanism, by which alcohol exacerbates liver injury in HIV-infection. Alcohol also potentiates HIV-induced apoptosis of hepatocytes [8] , thereby causing intensive activation of Kupffer cells and HSC and promotion of inflammation and apoptosis in HIV-infected alcohol-abusing patients [54] .
CONCLUSION
HIV induces liver injury by direct interactions with parenchymal and non-parenchymal liver cells. These HIV-infected liver cells, in turn cross-talk with uninfected cells, thereby causing the spread of liver injury. Multiple mechanisms can be attributed to the role of HIV in promoting liver inflammation and fibrosis. The most important are pro-apoptotic effects of HIV on hepatocytes and HIV-associated microbial translocation and microbiota changes. In addition to cytotoxic effects of HIV on hepatocytes and activation of non-parenchymal liver cells, ART also promotes liver injury due to drug toxicity and/or drug metabolism, mitochondrial damage, immunosuppression and drug hypersensitivity reactions. The effects of HIV-infection on liver cells are tremendously potentiated by second hits, and alcohol is most important of them. Proper management of HIV-infected patients requires recognition of liver injury conditions for effective targeted diagnosis and treatment.
